Enoxaparin

Padayachee, N.; Schoeman, N.; Schellack, Natalie

dc.contributor.author	Padayachee, N.
dc.contributor.author	Schoeman, N.
dc.contributor.author	Schellack, Natalie
dc.date.accessioned	2022-07-29T06:55:25Z
dc.date.available	2022-07-29T06:55:25Z
dc.date.issued	2021-05
dc.description.abstract	The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality.	en_US
dc.description.department	Pharmacology	en_US
dc.description.uri	http://www.sapj.co.za	en_US
dc.identifier.citation	Padayachee N., Schoeman N. & Schellack, N. 2021, 'Enoxaparin', SA Pharmaceutical Journal, vol. 88, no. 2, pp. 26-29, doi : 10.10520/ejc-mp_sapj_v88_n2_a7.	en_US
dc.identifier.issn	2221-5875 (print)
dc.identifier.issn	2220-1017 (online)
dc.identifier.other	10.10520/ejc-mp_sapj_v88_n2_a7
dc.identifier.uri	https://repository.up.ac.za/handle/2263/86582
dc.language.iso	en	en_US
dc.publisher	Medpharm Publications	en_US
dc.rights	Medpharm Publications. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License.	en_US
dc.subject	Enoxaparin	en_US
dc.subject	Coagulopathy	en_US
dc.subject	Factor Xa	en_US
dc.subject	Low-molecular weight heparin (LMWH)	en_US
dc.subject	COVID-19 pandemic	en_US
dc.subject	Coronavirus disease 2019 (COVID-19)	en_US
dc.subject	Thrombotic conditions	en_US
dc.title	Enoxaparin	en_US
dc.type	Article	en_US